miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL

First-line treatment for osteosarcoma includes chemotherapy and surgery. However, the five-year survival rate of refractory osteosarcoma remains unsatisfactory. Osteosarcoma cancer stem cells, possessing stemness and chemoresistance, are one of the critical causes of poor response to chemotherapy. E...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingyong, Wang, Shubao, Bai, Yang, Ali, Aasi Mohammad, Deng, Jiewen, Chen, Yushi, Fu, Yonghui, He, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917813/
https://www.ncbi.nlm.nih.gov/pubmed/36769824
http://dx.doi.org/10.3390/jcm12031177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917813/
https://www.ncbi.nlm.nih.gov/pubmed/36769824
http://dx.doi.org/10.3390/jcm12031177

Ejemplares similares